In a significant development for Canada’s financial landscape, Apotex Health Corp., the nation’s largest pharmaceutical manufacturer, has revised its initial public offering (IPO) plans, increasing the target to $1.3 billion. The company will price its shares at £24 on the Toronto Stock Exchange, a move that reflects robust investor interest. Originally aiming to raise £1 billion with shares priced between £20 and £24, Apotex’s new strategy indicates a 30 per cent increase in its fundraising ambitions.
Strong Demand Drives Increased Offering
According to sources familiar with the situation, Apotex has opted to price its shares at the upper end of its previously established range, a decision likely influenced by the strong demand from investors. The company is expected to officially announce the revised offering size and pricing after market hours on Tuesday, with trading anticipated to commence on Wednesday.
This enhanced offering allows Apotex’s private equity backers, along with other shareholders, to increase their stake in the company. Initially projected to sell £150 million worth of shares, they will now divest £450 million. The remaining £850 million will bolster Apotex’s financial position, primarily aimed at debt reduction.
A Positive Sign for Canadian Markets
This upsizing is viewed as a hopeful sign for Canada’s capital markets, which have struggled to attract IPOs in recent years. While technology companies saw a surge of public listings early in the COVID-19 pandemic, many have since faced declining share values, leading to several firms being sold to private equity at lower valuations. The Apotex IPO is set to be the largest in Canada since Definity Financial Corp.’s £1.4 billion offering in 2021.
However, the backdrop of fluctuating American stock markets adds an element of caution. The Nasdaq Composite Index experienced a nearly 1 per cent drop on Tuesday and has seen a total decline of almost 5 per cent over the past week. Continued market volatility could impact the performance of Apotex’s shares post-IPO.
Apotex’s Growth and Strategic Acquisitions
Founded in 1974 by the late Barry Sherman, Apotex has established itself as a leader in the production of generic medications, often entering fierce legal battles over drug patents. With a workforce exceeding 6,500, the company produces approximately 25 billion doses of medication annually, serving markets across 70 countries. In the last fiscal year, sales distribution was roughly 45 per cent from Canada, 46 per cent from the United States, and the remainder from international markets.
Following the tragic deaths of Sherman and his wife, Honey, in December 2017, Apotex was acquired by New York-based SK Capital Partners LP, a private equity firm with a focus on life sciences. Through the upcoming IPO, SK will sell a portion of its stake while retaining significant ownership.
In recent years, Apotex has diversified its product offerings, launching into areas beyond generic pills to include liquids, inhalers, and topicals, as well as biosimilars. Notably, in 2024, the company acquired Searchlight Pharma Inc. for £502 million, marking a strategic shift into the realm of patented drugs. This was followed by the purchase of CanPrev Natural Health Products for £184.5 million, a move that positioned Apotex in the growing vitamins market.
Despite these expansions, Apotex’s debt has surged, now standing at £2.9 billion as of March 31—more than doubling within two years. In July 2025, the company also undertook a recapitalisation, distributing a £1.1 billion dividend to select shareholders.
Why it Matters
The successful upsizing of Apotex’s IPO not only represents a critical moment for the company but also signals potential revitalisation within the Canadian capital markets, which have been sluggish in recent years. As investors seek opportunities in a challenging economic climate, the outcome of this IPO could set the tone for future public offerings in the sector. The unfolding narrative around Apotex and its strategic growth initiatives reflects the evolving landscape of pharmaceuticals, emphasizing innovation and resilience in times of uncertainty.
